Pilot Study to Evaluate the Feasibility, Adherence and Acceptance of the MiDiálisis Platform for Patients on PD
NCT ID: NCT07326085
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
55 participants
INTERVENTIONAL
2025-07-27
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
NCT04034966
Integrated Patient Care Intradialysis Programme in Hemodialysis Through a Virtual Health Platform
NCT04823286
A Prospective, Open-label, Multi-center Pilot Study to Evaluate the Safety, Feasibility and Usability of the IDA
NCT05342935
Evaluation of the Effectiveness of a Mobile Application Developed for Hemodialysis Patients.
NCT07211100
Assisted Peritoneal Dialysis: A Feasibility Study
NCT04319185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. The patient will enter their blood pressure and ultrafiltration values.
2. They will receive a digital scale that sends their weight and body composition to the MiDiálisis app via Bluetooth.
3. They will receive a smartband that sends information about their heart rate, sleep pattern, and physical activity to the MiDiálisis app via Bluetooth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INTERVENTION
This group will recived the smart band, smart scale and the APP
Patients will connect the smartband.
Patients will connect the smartband to the application via Bluetooth.
Smart band
During Phase 2, patients will use the smart band continuously throughout the day.
Smart scale
During Phase 2, patients will weigh themselves daily using the scale.
MiDialisis App
Patients will enter daily blood pressure data and information related to their peritoneal dialysis therapy.
Patients will install the app during the phase 2.
Patients will download and begin using the application.
Patients will connect the digital scale.
Patients will connect the digital scale to the application via Bluetooth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients will connect the smartband.
Patients will connect the smartband to the application via Bluetooth.
Smart band
During Phase 2, patients will use the smart band continuously throughout the day.
Smart scale
During Phase 2, patients will weigh themselves daily using the scale.
MiDialisis App
Patients will enter daily blood pressure data and information related to their peritoneal dialysis therapy.
Patients will install the app during the phase 2.
Patients will download and begin using the application.
Patients will connect the digital scale.
Patients will connect the digital scale to the application via Bluetooth.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with chronic kidney disease who have been on PD for at least 3 months in the same hospital.
* Patients with a stable clinical condition during the 3 months prior to entering the study, defined as no unscheduled hospitalizations or major cardiovascular events (myocardial infarction or stroke) during that period.
* Availability of a smartphone or tablet and internet access for the patient/caregiver.
* Patients who understand the nature of the study and sign the informed consent form.
Exclusion Criteria
* Patients who do not routinely use a smartphone or are unfamiliar with the use of mobile applications.
* Patients who are scheduled for a living kidney transplant in the next 6 months.
* Patients with a life expectancy of less than 6 months.
* Patients in a peritoneal ultrafiltration program due to cardiorenal syndrome.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spanish Society of Nephrology
OTHER
SOMANE (MADRID SOCIETY OF NEPHROLOGY)
UNKNOWN
Foundation for Biomedical Research of the Hospital Universitario 12 de Octubre
UNKNOWN
Aida Frías González
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aida Frías González
M.D., Nephrologist at Universitary Hospital 12 de Octubre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudia Yuste Lozano, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital 12 de Octubre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital 12 de Octubre
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23/187
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.